OIPE IAP43
SEP 26 2005
PATENT & TRADEMARK OFFICE

TITLE: METHODS AND COMPOSITIONS FOR...
FIRST NAMED INVENTOR: Chichang Lee
APP#: 10/003,632
ATTY: Guy Kevin Townsend TEL. #: 732-524-2517
DOCKET #: CEN-0269 CUST. #: 000027777

FIG. 1



TITLE: METHODS AND COMPOSITIONS FOR...
FIRST NAMED INVENTOR: Chichang Lee
APP#: 10/003,632
ATTY: Guy Kevin Townsend TEL. #: 732-524-2517
DOCKET #: CEN-0269 CUST. #: 000027777

FIG. 2



TITLE: METHODS AND COMPOSITIONS FOR...
FIRST NAMED INVENTOR: Chichang Lee
APP#: 10/003,632
ATTY: Guy Kevin Townsend TEL. #: 732-524-2517
DOCKET #: CEN-0269 CUST. #: 000027777

FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D



FIG. 4


Relative Titer
50
40
30
20
10
0
17
12
10
7
5
3
0
Days
120
80
40
0
% Viability
IgG R, IgG
IgG R/ hBCL-2, IgG
IgG R, % Viability
IgG R/ hBCL-2,%

FIG. 5A


Total cells/ml in CM2 complete media
Sp2/0
Sp2/0-Bcl2
3GEP1
Total cells/ml (10e6)
0
1
2
3
4
5
2.0
4.0
7.0
8.0
9.0
10.0
11.0
Days in culture

FIG. 5B


Viable cells in CM2 complete media
Sp2/0
Sp2/0Bcl-2
3GEpool1
Viable cells/ml (10e6)
0
1
2
3
4
2.0
4.0
7.0
8.0
9.0
10.0
11.0
Days in culture

FIG. 5C


Percent viability in
CM2 complete media
100
50
0
% viability
2.0
4.0
7.0
8.0
9.0
10.0
11.0
Days in culture
Sp2/0
Sp2/0-Bcl2
3GEP1

FIG. 5D


Cell doubling time(hrs.)
in CM2 complete media
50
40
30
20
10
0
Hours
2.0
4.0
7.0
Days in culture
Sp2/0
Sp2/0-Bcl2
3GEP1

FIG. 6


A.
Heavy Chain (H.C.)
Ladder
Sp2/0
IgG R
A-C4/hBCL-2
1
2
3
4
5
β-actin
H.C.
2.4Kb
1.4Kb
B.
Light Chain (L.C.)
Sp2/0
IgG R
A-C4/hBCL-2
1
2
3
4
5
β-actin
L.C.
2.4Kb
1.4Kb

FIG. 7A


Viability in SFM
w/o Primatone & Albumin
100
80
60
40
20
%
IgG M
IgG M/Bcl-2
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17 P18
Passages

FIG. 7B


Total Cell Density
in SFM w/o Primatone & Albumin
1.2
0.8
0.4
0
IgG M
IgG M/Bcl-2
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17 P18
Passages

FIG. 8A


IgG Titers
10
7.5
5
2.5
0
Relative Values
Day 4
Day 7
IgG M
IgG M/Bcl-2
IgG M
IgG M/Bcl-2
SFM
SFM w/o PA

FIG. 8B


Specific Productivity
10
8
6
4
2
0
Relative Values
Day 4
Day 7
IgG M
IgG M/Bcl-2
IgG M
IgG M/Bcl-2
SFM
SFM w/o PA

FIG. 9


Relative Titer
160
120
80
40
0
16
13
9
7
5
2
0
Days
IgG R, IgG
IgG R/ hBCL-2, IgG
IgG R, % Viability
IgG R/ hBCL-2,% Viability
120
80
40
0
% Viability

FIG. 10


Relative Titer
60
50
40
30
20
10
0
17
13
12
11
10
9
8
7
6
5
4
3
2
1
Days
IgG R, Titer
IgG R/ hBCL-2, Titer
IgG R, VCD
IgG R/ hBCL-2, VCD
IgG R, TCD
IgG R/ hBCL-2, TCD
8
7
6
5
4
3
2
1
0
Density

FIG. 11A



FIG. 11B



FIG. 11C



FIG. 11D



FIG. 12


IgG Relative Value
2
1
Day
Ab (mg/L)
Total 10e6 cells/mL
Rx cnt viab 10e6 cells/mL
% viab
c/mL
9.00
8.00
7.00
6.00
5.00
4.00
3.00
2.00
1.00
0.00

TITLE: METHODS AND COMPOSITIONS FOR...
FIRST NAMED INVENTOR: Chichang Lee
APP#: 10/003,632
ATTY: Guy Kevin Townsend TEL. #: 732-524-2517
DOCKET #: CEN-0269 CUST. #: 000027777

FIG. 13